Table 1 General characteristics of the study participants at baseline.
Variables | Placebo group (n = 50) | Folic acid group (n = 50) | P-value |
|---|---|---|---|
Male, n (%) | 23 (46) | 22 (44) | 0.841 |
Age (years) | 54.46 ± 7.81 | 52.86 ± 9.46 | 0.36 |
Duration of diabetes (years) | 7.14 ± 3.76 | 7.82 ± 3.94 | 0.38 |
Hypertension, n (%) | 27 (54) | 23 (46) | 0.424 |
Hyperlipidemia, n (%) | 14 (28) | 12 (24) | 0.648 |
Smoker, n (%) | 17 (34) | 15 (30) | 0.668 |
ACEIs use, n (%) | 19 (38) | 23 (46) | 0.418 |
ARB use, n (%) | 17 (34) | 21 (42) | 0.410 |
BB use, n (%) | 7 (14) | 3 (6) | 0.182 |
CCB use, n (%) | 10 (20) | 11 (22) | 0.806 |
OHA Co-treatment with Metformin | |||
Glimepiride, n (%) | 20 (50) | 25 (50) | 0.315 |
Glibenclamide, n (%) | 18 (36) | 15 (30) | 0.523 |
Vildagliptin, n (%) | 12 (24) | 10 (20) | 0.629 |
